Related Experiment Video
Updated: Aug 10, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
From bench to bedside: GP IIb-IIIa inhibitors
1Coronary Care Unit, Northwestern University School of Medicine, Chicago, Illinois 60611, USA.
Abstract:
Our understanding of the pathophysiology of acute coronary syndromes (ACS) has now been substantiated by many studies showing that atherothrombosis plays a predominant role. This article reviews the molecular interactions in thrombosis that may serve as therapeutic targets for more effective management of these syndromes. In particular, the discovery of the fact that the glycoprotein (GP) IIb-IIIa receptor plays a central and common role in platelet-mediated thrombosis has focused the therapeutic efforts. Blockade of this receptor has emerged as a new and potent strategy for inhibition of platelet aggregation and thus of clot formation. A number of trials have now corroborated the need for such antithrombotic drugs in the management of patients with non-ST-segment elevation ACS.
More Related Videos
11:17Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
Published on: August 30, 2018
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Related Concept Videos
Cardiovascular Drugs: Classification based on Therapeutic Indications
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Bioequivalence studies: Biowaivers
Drug Dosing: Geriatric Patients
Venous Thrombosis III: Interprofessional Care